Copyright
©The Author(s) 2017.
World J Gastrointest Oncol. Mar 15, 2017; 9(3): 121-128
Published online Mar 15, 2017. doi: 10.4251/wjgo.v9.i3.121
Published online Mar 15, 2017. doi: 10.4251/wjgo.v9.i3.121
Table 1 Baseline patient demographics
| Characteristic | n (%) |
| Median age (range) (yr) | 63.8 (26.9-89.0) |
| Ethnicity | |
| Chinese | 203 (74.9) |
| Indian | 13 (4.8) |
| Malay | 20 (7.4) |
| Others | 35 (12.9) |
| Gender | |
| Male | 134 (49.4) |
| Female | 137 (50.6) |
| ECOG status | |
| 0 | 89 (32.8) |
| 1 | 135 (49.8) |
| 2 | 28 (10.3) |
| 3 | 11 (4.1) |
| 4 | 8 (3.0) |
| ASA score | |
| 1 | 107 (39.5) |
| 2 | 128 (47.2) |
| 3 | 36 (13.3) |
| Comorbidities | |
| Diabetes mellitus | 56 (20.7) |
| Hypertension | 124 (45.8) |
| Cardiac comorbidities | 43 (15.9) |
| Respiratory comorbidities | 15 (5.5) |
| Chronic renal impairment | 10 (3.7) |
| Central nervous system comorbidity | 19 (7.0) |
| Previous cancer | 27 (10.0) |
| Cigarette smoking | 58 (21.4) |
| Regular alcohol use | 31 (11.4) |
Table 2 Baseline gastric cancer-related characteristics
| Characteristic (n = 271) | n (%) |
| Presentation of peritoneal metastases | |
| At initial gastric cancer diagnosis | 258 (95.2) |
| Recurrence of treated gastric cancer | 13 (4.8) |
| Site of metastases | |
| Peritoneal only | 217 (80.1) |
| Peritoneal and distant site(s) | 54 (19.9) |
| Primary gastric cancer location | |
| Gastroesophageal junction | 23 (8.5) |
| Proximal gastric | 16 (5.9) |
| Gastric body | 101 (37.3) |
| Distal gastric | 103 (38.0) |
| Linitis plastica | 28 (10.3) |
| Lauren’s classification | |
| Intestinal | 129 (47.6) |
| Diffuse | 142 (52.4) |
| c-erb-B2 receptor status (n = 195) | |
| Positive | 37 (19.0) |
| Negative | 158 (81.0) |
Table 3 First-line chemotherapy regime
| Chemotherapy regime (n = 171) | n (%) |
| Anthracycline + platinum-based agent + nucleotide analogue Examples epirubicin + cisplatin + 5-fluorouracil epirubicin + oxaliplatin + 5-fluorouracil | 13 (7.6) |
| Platinum-based agent + nucleotide analogue Examples cisplatin + 5-fluorouracil oxaliplatin + capecitabine cisplatin + S-1 | 97 (56.7) |
| Nucleotide analogue monotherapy Examples 5-fluorouracil capecitabine S-1 | 30 (17.5) |
| FOLFOX (5-fluorouracil + leucovorin + oxaliplatin) | 24 (14.0) |
| Other regimes (e.g., Docetaxel + cisplatin + 5-fluorouracil) | 7 (4.2) |
Table 4 Reasons requiring unplanned hospitalizations
| Reason (n = 201) | n (%) |
| Symptomatic ascites | 64 (31.8) |
| Sepsis | 64 (31.8) |
| Gastric outlet obstruction | 60 (29.9) |
| Bleeding GIT | 60 (29.9) |
| Intestinal obstruction | 59 (29.4) |
| Chemotherapy-related toxicity | 23 (11.4) |
| Obstructive jaundice | 17 (8.5) |
| Obstructive uropathy | 17 (8.5) |
| Tumour perforation | 7 (3.5) |
Table 5 Therapeutic interventions required
| Treatment category | Treatment | n (%) |
| Surgery | Palliative gastrectomy | 32 (36.0) |
| n = 89 (32.8%) | Surgical bypass | 46 (51.7) |
| Open gastrostomy | 2 (2.2) | |
| Feeding jejunostomy | 5 (5.6) | |
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy | 1 (1.1) | |
| Others | 3 (3.3) | |
| Endoscopic intervention | Feeding tube insertion only | 45 (78.9) |
| n = 57 (21.0%) | Stenting only | 8 (14.0) |
| Feeding tube insertion and stenting | 4 (7.0) | |
| Radiotherapy | Radiotherapy to gastric tumour | 29 (82.9) |
| n = 35 (12.9%) | Radiotherapy to other sites | 6 (17.1) |
- Citation: Tan HL, Chia CS, Tan GHC, Choo SP, Tai DWM, Chua CWL, Ng MCH, Soo KC, Teo MCC. Gastric peritoneal carcinomatosis - a retrospective review. World J Gastrointest Oncol 2017; 9(3): 121-128
- URL: https://www.wjgnet.com/1948-5204/full/v9/i3/121.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v9.i3.121